NCT04822415View on ClinicalTrials.gov

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

NACompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Symptomatic Irreversible Pulpitis
Interventions
DRUG

Mepivacaine

IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

DRUG

Articaine

IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

All Listed Sponsors
lead

Cairo University

OTHER

NCT04822415 - Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis | Biotech Hunter | Biotech Hunter